Conclusion: Finally, several cases of homocystinuria associated with dystonia, and some recent reports of elevated Hcy in patients with primary adult onset dystonia have been published. Increased Hcy plasma levels may have important implications in patients affected by these basal ganglia disturbances, by exerting neurotoxic effects, contributing to neurotransmitter imbalance in motor circuits, and increasing the risk for vascular insults and cognitive dysfunctions.
PubMed 16842141 ↗L-Dopa
The short answer. Most people who report on L-Dopa say it did not help (only 30% of 30 positive). It is most often used for energy: 80% of 10 reports say that improved. It is well studied — 47 meta-analyses on PubMed.
From 90 mentions in total — the rest didn't say how it went and aren't counted.
What L-Dopa does, according to users
Of the people who reported each effect, the share who said it got better.
4 more with fewer than 3 reports
What the research says
Systematic reviews and meta-analyses from PubMed, with their published conclusions.
3+ meta-analyses or systematic reviews and 10+ randomized controlled trials in humans. The grade measures how much human research exists — read the conclusions below for what it found. 47 meta-analyses on PubMed ↗ · 286 randomized trials ↗
Conclusion: In PD patients experiencing motor fluctuations, adjunctive PER did not improve the motor state and was well-tolerated at the lower doses.
PubMed 29159466 ↗Conclusion: We conclude that nicotine appears to have efficacy in animal models of LID. Large randomized clinical trials testing the effect of nicotine in PD patients with LID are warranted.
PubMed 24510151 ↗Conclusion: Opioids seem to be effective for treating RLS symptoms, but there are no definitive data regarding the important problem of safety. This conclusion is based on only one study with a high dropout rate (moderate quality evidence).
PubMed 27355187 ↗183 human trials on ClinicalTrials.gov test L-Dopa — 125 completed, 14 recruiting now. See all on ClinicalTrials.gov ↗
- PET Scanning in Parkinson s Disease · Schizophrenia, Parkinson's Disease
- Positron Emission Tomography (PET) Imaging in People With Gaucher Mutations · Parkinson Disease, Gaucher Disease
- A Targeted Amino Acid Supplement for People With Parkinson's Disease · Parkinson Disease, Idiopathic · 2025
What government agencies say
Official records from US, Canadian and EU regulators, each linked to its source.
NIH has funded 48 research projects with L-Dopa in the title, $32,109,932 in total (1985–2026). NIH RePORTER ↗
Dosage people report
As stated by users — not a recommendation. Follow the label or your doctor.
Reported side effects
How often each side effect came up across all reports.
What users say
First-hand experiences, quoted verbatim. We show one positive and one negative where both exist.
“I find 4-hydroxyphenylalanine and L-γ-glutamylethylamide make a huge difference in keeping myself on an even keel..”
“L-Dopa is making me a bit anxious but sure helps me with depression and focus.”
“I have been taking L-Dopa and it has been working for me. My moods have been consistent and my anxiety have been almost non-existent.”
“I've taken both L-Dopa and 5-HTP before and they didn't do shit.”
Other options for energy
Sources
- User reports: 90 mentions in public discussions, quoted with a link to each discussion (e.g. this thread ↗).
- PubMed (US National Library of Medicine, NIH): meta-analyses ↗ · randomized trials ↗
- ClinicalTrials.gov (NIH): registered trials ↗
- NIH RePORTER ↗
User data from public discussions; research from PubMed. Information only, not medical advice — talk to a doctor before starting, stopping or combining anything. Data updated October 5, 2026. How we rate